Overview
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2024-10-01
2024-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitisPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Escient Pharmaceuticals, Inc
Criteria
Inclusion Criteria:- Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
- BSA of 3% to 20% and a vIGA-AD score of ≥3
Exclusion Criteria:
- Other active skin diseases associated with chronic pruritus
- Clinically infected atopic dermatitis that requires antibiotic therapy
- Use of specific treatments for atopic dermatitis